Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Serrano

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Contemporary Clinical Trials|July 3, 2021
Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trialAliana Guerrieri-Gonzaga, Davide Serrano, Parjhitham Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2026
Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled AnalysisSara Gandini, Aliana Guerrieri-Gonzaga, Davide Serrano, et al.
Tumori|May 18, 2019
WITHDRAWAL-Administrative Duplicate Publication: The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention EuropeCarolina Espina, Linda Bauld, Bernardo Bonanni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2023
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 StudyMatteo Lazzeroni, Matteo Puntoni, Aliana Guerrieri-Gonzaga, et al.
NPJ Breast Cancer|January 18, 2024
Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulationHarriet Johansson, Aliana Guerrieri-Gonzaga, Sara Gandini, et al.
Journal of the National Cancer Institute|August 7, 2024
Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedulesDavide Serrano, Harriet Johansson, Bjørn-Erik Bertelsen, et al.
JAMA Oncology|March 23, 2023
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical TrialDavide Serrano, Sara Gandini, Parjhitham Thomas, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 30, 2025
Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety AnalysisIrene Maria Briata, Stefano Spinaci, Parijatham S Thomas, et al.
Nature Medicine|April 3, 2019
Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancerJakob Wirbel, Paul Theodor Pyl, Ece Kartal, et al.
Nature Medicine|April 3, 2019
Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradationAndrew Maltez Thomas, Paolo Manghi, Francesco Asnicar, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Contemporary Clinical Trials|July 3, 2021
Alternative dosing of exemestane in postmenopausal women with ER-positive breast cancer. Design and methods of a randomized presurgical trialAliana Guerrieri-Gonzaga, Davide Serrano, Parjhitham Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2026
Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled AnalysisSara Gandini, Aliana Guerrieri-Gonzaga, Davide Serrano, et al.
Tumori|May 18, 2019
WITHDRAWAL-Administrative Duplicate Publication: The essential role of prevention in reducing the cancer burden in Europe: a commentary from Cancer Prevention EuropeCarolina Espina, Linda Bauld, Bernardo Bonanni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 14, 2023
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 StudyMatteo Lazzeroni, Matteo Puntoni, Aliana Guerrieri-Gonzaga, et al.
NPJ Breast Cancer|January 18, 2024
Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulationHarriet Johansson, Aliana Guerrieri-Gonzaga, Sara Gandini, et al.
Journal of the National Cancer Institute|August 7, 2024
Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative schedulesDavide Serrano, Harriet Johansson, Bjørn-Erik Bertelsen, et al.
JAMA Oncology|March 23, 2023
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical TrialDavide Serrano, Sara Gandini, Parjhitham Thomas, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 30, 2025
Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety AnalysisIrene Maria Briata, Stefano Spinaci, Parijatham S Thomas, et al.
Nature Medicine|April 3, 2019
Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancerJakob Wirbel, Paul Theodor Pyl, Ece Kartal, et al.
Nature Medicine|April 3, 2019
Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradationAndrew Maltez Thomas, Paolo Manghi, Francesco Asnicar, et al.
Pageof 9